ClinicalTrials.gg
CompletedNCT05283538CACD1Updated Oct 22, 2026Results posted

Cardiovascular Risk Stratification in Young People With Type 1 Diabetes

An interventional study of Coronary Artery Calcification Realization in Type 1 Diabetes and Coronary Artery Calcification, sponsored by Poitiers University Hospital. Completed at 1 site in France. Open to participants aged 18 Years to 35 Years. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by Poitiers University Hospital · Not applicable, Interventional, and Diagnostic

How we know

Updated Oct 22, 2026Results postedStudy documents posted+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
91
Allocation
Not applicable
Ages
18 Years to 35 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 271 studies in Diabetes Mellitus, Type 1 with a site in France — 39 open to participants now, 45 under way, 8 of them phase 3. Diabetes Mellitus, Type 1 · France.

Enrollment
81st of 193
91 · median 67
Started
2022
with 13 others
No phase
103 of 271
9 open now
Registered
208th of 271
by date

Among the 271 studies in Diabetes Mellitus, Type 1 with a site in France, this one is the 81st largest by enrollment of the 193 interventional ones that give a count, is one of 14 that started in 2022, is one of 103 with no phase, and was the 208th registered.

Diabetes Mellitus, Type 1

3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

39 of the 271 studies in Diabetes Mellitus, Type 1 with a site in France are open now. Recruiting first, the newest first:

34 more — sign in →

All 39 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 18 Years to 35 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 271 studies in Diabetes Mellitus, Type 1 with a site in France, or all of them as a file.
02

Study summary

The aim of the study is to compare ESC recommendations on cardiovascular (CV) risk stratification with the achievement of a CAC (Coronary Artery Calcification).

The development of a CAC, currently not systematically offered to these patients to refine CV risk, could make it possible to offer more intensive management of CV risk facors for patients who objectively have a high CV risk as evidenced by a high coronary calcium score.

LDL target recommandations have become more aggressive with a very high level of evidence in type 2 diabetic patients but low in type 1 diabetic patients because there is no specific CV intervention study for T1D patients.

These recommendations have far-reaching consequences because they would justify introducing in young type 1 diabetic patients, considered from the outset to be at moderate cardiovascular risk (young T1DM \<35 years old) or even at high cardiovascular risk (duration of diabetes > 10 years) or very high cardiovascular risk (duration of diabetes > 20 years), treatment with statins or even aspirin, based only on the length of time they have had diabetes.

The realization of a CAC, currently not systematically offered to these patients to refine CV risk, could make it possible to propose a more intensive management of CV risk factors for patients with objectively high CV risk attested by a high coronary calcium score.

In this case the introduction of treatment with statins would be indicated.

03

Conditions studied

  • Type 1 Diabetes
  • Coronary Artery Calcification

Keywords

  • cardio-vascular
  • c reactive protein
04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged ≥ 18 years and ≤ 35 years; Type 1 diabetic patient (defined by T1DM antibody positivity or onset in pediatric age); In primary cardiovascular prevention (with no CV events); Patient not treated by statins; Duration of diabetes > 5 years; Equipped with a continuous interstitial glucose measurement system for at least 14 days; No previous CAC performed Patient with social security or with third party coverage. Free subject, without guardianship or curatorship or subordination; signed by the patient after clear and fair information about the study.

Exclusion criteria

Exclusion Criteria:

  • Cardiovascular secondary prevention patients (with a previous CV event); abnormality suggestive of coronary ischemia; Intolerance or to statins Person benefiting from reinforced protection, namely minors, persons deprived of their liberty by a judicial or administrative decision, persons staying in a health or social establishment, adults under legal protection and finally patients in emergency situations; Pregnant and/or breastfeeding woman.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
91 participants (actual)

Study arms

  • Experimental
    Coronary Artery Calcification Evaluation

    Diagnostic Test: Coronary Artery Calcification Realization

Interventions

  • Diagnostic testCoronary Artery Calcification Realization

    Coronary Artery Calcification Realization

06

What researchers measure

Primary outcomes

  1. Change of Statin Prescription Indication Between Consensus of the French Society of Cardiology and the French Speaking Society of Diabetology 2020 and the ESC/EASD Consensus

    Patients for whom the indication for prescribing statins for primary prevention would change if the CAC score were used as a diagnostic tool for cardiovascular risk instead of the 2019 ESC/EASD guidelines in patients with type 1 diabetes aged 18 to 35.

    Time frame: 1 day

07

Results

Posted Oct 22, 2026

Participant flow

Participant flow — Overall Study
MilestoneCoronary Artery Calcification Evaluation
Started91
Completed85
Not completed6

Outcome measures

PrimaryChange of Statin Prescription Indication Between Consensus of the French Society of Cardiology and the French Speaking Society of Diabetology 2020 and the ESC/EASD Consensus

Patients for whom the indication for prescribing statins for primary prevention would change if the CAC score were used as a diagnostic tool for cardiovascular risk instead of the 2019 ESC/EASD guidelines in patients with type 1 diabetes aged 18 to 35.

Time frame:
1 day
Reported as:
Count of participants · Participants
Change of Statin Prescription Indication Between Consensus of the French Society of Cardiology and the French Speaking Society of Diabetology 2020 and the ESC/EASD Consensus
ParticipantsChange of Statin Prescription Indication Between Consensus of the French Society of Cardiology and t
Change of Statin Prescription Indication Between Consensus of the French Society of Cardiology and the French Speaking Society of Diabetology 2020 and the ESC/EASD Consensus32

Adverse events

Collected over 1 day. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Coronary Artery Calcification Evaluation0/91 (0%)0/91 (0%)0/91 (0%)

Baseline characteristics

Patients with available primary outcome measures.

Age, Continuous
Age, Continuous(year)Coronary Artery Calcification Evaluation
Mean24.5 ± 4.4
Sex: Female, Male
Sex: Female, Male(Participants)Coronary Artery Calcification Evaluation
Female44
Male41
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Coronary Artery Calcification Evaluation
08

Study locations

1 site
  • C.H.U. de Poitiers
    Poitiers, 86000, France
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2022 to primary completion in Mar 2025, 36 months.

Results were first posted in Oct 2026, 1 year 6 months after primary completion.

Of 852 non-industry interventional studies with no phase under Diabetes Mellitus, Type 1, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 37. This study's 36 months is above that.

Counting every sponsor, half of 957 studies reached it within 18 months; a quarter within 9 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 4, 2022
First posted
Mar 17, 2022
StartActual
Mar 28, 2022
Primary completionActual
Mar 28, 2025
CompletionActual
Mar 28, 2025
Results first posted
Oct 22, 2026
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 22, 2026
Primary outcomes
1 added, 2 removed
What changed in the outcomes
  • AddedChange of Statin Prescription Indication Between Consensus of the French Society of Cardiology and the French Speaking Society of Diabetology 2020 and the ESC/EASD ConsensusTime frame: 1 day
  • RemovedStatin prescription indication based on the patient's LDL cholesterol value and the LDL cholesterol target determined according to the cardiovascular risk level calculated with the coronary calcium scoreTime frame: 1 day
  • RemovedStatin prescription indication based on the patient's LDL cholesterol value and the LDL cholesterol target determined according to the cardiovascular risk level according to the ESC/ESA 2019 recommendationsTime frame: 1 day
Oct 22, 2026
Documents
Title
Comparison of Cardiovascular Risk Stratification in Young People With Type 1 Diabetes by Coronary Calcium Score to ESC/ESA2019 Recommendations
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    Results posted
    Primary outcomes 1 added, 2 removed
    What changed in the outcomes
    • AddedChange of Statin Prescription Indication Between Consensus of the French Society of Cardiology and the French Speaking Society of Diabetology 2020 and the ESC/EASD ConsensusTime frame: 1 day
    • RemovedStatin prescription indication based on the patient's LDL cholesterol value and the LDL cholesterol target determined according to the cardiovascular risk level calculated with the coronary calcium scoreTime frame: 1 day
    • RemovedStatin prescription indication based on the patient's LDL cholesterol value and the LDL cholesterol target determined according to the cardiovascular risk level according to the ESC/ESA 2019 recommendationsTime frame: 1 day
    Title Comparison of Cardiovascular Risk Stratification in Young People With Type 1 Diabetes by Coronary Calcium Score to ESC/ESA2019 Recommendations
    + 5 other changes: verification date, oversight details, conditions, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05283538
Responsible party
Sponsor
First posted
Mar 17, 2022
Start date
Mar 28, 2022
Primary completion
Mar 28, 2025
Completion
Mar 28, 2025
Results posted
Oct 22, 2026
Last update
Oct 22, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion